Lv5
1260 积分 2026-01-12 加入
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
1个月前
已完结
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
1个月前
已完结
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
3个月前
已完结
Perioperative approaches for patients with biliary tract cancer
3个月前
已完结
Inactivating LATS2 Variation Drives Tumor Progression and Resistance to Anti-PD-1 Therapy in Intrahepatic Cholangiocarcinoma
3个月前
已关闭
Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability
5个月前
已完结
Biology of IDH mutant cholangiocarcinoma
5个月前
已完结
Cholangiocarcinoma — novel biological insights and therapeutic strategies
5个月前
已完结
Cancer cell metabolism and antitumour immunity
6个月前
已完结
From geroscience to precision geromedicine: Understanding and managing aging
6个月前
已完结
皖公网安备34019202002308
